Thymosin alpha 1 peptide (TA1): why people use it, and what the trials were actually for

Thymosin alpha 1 peptide, usually shortened to TA1 or Tα1, occupies an unusual spot in the peptide conversation: it is one of the few research-market peptides that is also a genuine, licensed pharmaceutical, just not in the United States. In the US its following is mostly the immune-health crowd, who treat it as a way to stay well, and people also ask whether it has bodybuilding benefits. Neither use is what the trials actually tested. This page explains what thymosin alpha-1 is, why people use it, what the trials were for, how long trial courses ran, what is known about side effects, and what users report, with a primary source for every claim. It is educational only, and nothing here is medical advice. For how this peptide fits the wider landscape of approved drugs and unapproved compounds, start with our explainer on what peptides are.

What is thymosin alpha 1 peptide?

Thymosin alpha-1 is a 28-amino-acid peptide that the body produces naturally in the thymus, the small organ behind the breastbone where T cells mature. A comprehensive 2020 review in the World Journal of Virology describes it as “a 28 amino acid peptide originally isolated from the thymus”, and notes that because it is a polypeptide naturally present there, it “plays a fundamental role in the control of inflammation, immunity, and tolerance.” Its manufactured, synthetic copy is a drug called thymalfasin, sold under the brand name Zadaxin and given as an injection under the skin. So unlike a purely lab-invented compound, thymosin alpha-1 is a fragment of the body’s own immune machinery that has also been developed into a real medicine.

It is not a steroid, not a growth hormone and not one of the anabolic peptides marketed for muscle; it is an immune signaling molecule. “TA1 peptide,” “Tα1,” “thymosin alpha-1” and “thymalfasin” all refer to the same 28-amino-acid sequence. The name that causes the most trouble is the one it shares with a different peptide, covered next.

Thymosin alpha-1 vs thymosin beta-4 vs TB-500: what is the difference?

Searchers mix these up constantly because all three carry the word “thymosin.” The 2020 review is blunt that thymosin alpha 1 and thymosin beta 4 are two thymus-derived peptides with “vastly different chemical compositions and immunological actions.” The review notes that both are separated from thymosin fraction 5, a thymus extract.

The practical point: TB-500 is a thymosin beta-4 product, not a form of thymosin alpha-1. People who buy one expecting the other are buying a different molecule with a different job. Everything else on this page is about thymosin alpha-1 only.

How is thymosin alpha-1 thought to work?

Thymosin alpha-1 is thought to work by engaging the immune system’s threat sensors and helping key immune cells mature, but the detailed picture comes largely from laboratory and animal work rather than human studies. The 2020 review reports that it “functions as a toll-like receptor (TLR)-9 and TLR-2 agonist” in myeloid and dendritic cells. Dendritic cells are the immune system’s messengers: when they mature, they show fragments of a pathogen to T cells and set the direction of the response. Downstream, the review states that thymosin alpha-1 therapy “modulates and partially normalizes T-lymphocyte numbers and function” in the settings where it has been studied. The operative word is normalizes: the described action is nudging a disordered or depleted T-cell compartment back toward its normal range, not flooding the body with immune activity.

The mechanism that best captures its character is not pure stimulation but balance. A 2006 study in the journal Blood found that thymosin alpha-1 “affected T-helper cell priming and tolerance induction by human and murine DCs” and “induced IDO expression and function” in those cells. IDO is an enzyme that helps restrain immune activity, so switching it on is a braking signal, not an accelerating one. The authors concluded that thymosin-primed dendritic cells achieved “the induction of T-helper type 1 immunity within a regulatory environment”, meaning they mounted a defensive response and kept a lid on it at the same time. These are detailed mechanisms observed mostly in cells and rodents, not confirmed pathways of benefit in a living person, and that distinction is the one marketing most often blurs.

What is thymosin alpha 1 peptide used for?

As a licensed drug abroad, thymosin alpha-1 is used for chronic viral hepatitis: thymalfasin is “approved in more than 35 countries for treatment of hepatitis B and C”. Researchers have also tested it in severe sepsis, in COVID-19, as a vaccine-response booster and as an add-on in some cancer care. In the US, where it is not an approved drug, people mostly use it for general immune support and during illness.

The hepatitis use is older than it sounds. The same review notes that thymosin alpha 1 for hepatitis B “was only used in the era of interferon and is now obsolete” since direct antiviral drugs arrived, and that hepatitis C treatment with it has likewise been discontinued in their favor. Its main licensed use, in other words, has largely been superseded. For a deeper look at the immunology and at how the hepatitis, sepsis and COVID-19 research fits together, see our sister publication’s thymosin alpha-1 and immune modulation page, and for where it sits among peptides discussed for long-running illness, its overview of peptides and chronic conditions.

Why do people use thymosin alpha-1, and does it help lifters?

People use it mainly as a staying-well tool, and the clearest window into why is what they post. Our community tracker collected 13 posts about TA1 on X between July 9 and 16, 2026.

The immune-health crowd is the core of that conversation. Some users describe TA1 as a daily staple and credit it with knocking out early cold symptoms or keeping them healthy when people around them were sick, including one account of staying well on a cruise. Others describe seeking it out off-label for immune and antiviral purposes. The most-engaged post in our sample, a thread from @eliterecomp, notes that TA1 is approved in many countries but little known in US biohacking circles, and discusses its clinical data alongside off-label use. The appeal is easy to see: a peptide with a real drug history abroad and a reputation at home for colds.

Lifters also ask whether it has bodybuilding benefits. The trials cannot answer that. None of the trials cited on this page enrolled healthy lifters, athletes or people trying to avoid colds, and none measured training recovery, strength or body composition. Questions about “thymosin alpha 1 bodybuilding benefits” therefore have no trial evidence to point to, and none of the sources cited here describe a muscle-building action; it is an immune peptide.

What does the evidence actually show?

The human evidence for thymosin alpha-1 is suggestive but not definitive, and it comes from sick patients, mostly in trials run outside the United States. In summary:

The clearest single test is the ETASS trial, a multicenter, randomized, controlled study of thymosin alpha-1 in severe sepsis conducted across six tertiary teaching hospitals in China and published in Critical Care in 2013. In that trial, 28-day mortality was 26.0% in the thymosin alpha-1 group versus 35.0% in the control group, but the difference did not reach statistical significance on the primary endpoint: the relative risk of death was 0.74 (95% CI 0.54 to 1.02), with a P value of 0.062. A secondary measure of in-hospital mortality (28.7% versus 39.4%) did reach significance. A well-designed trial found a signal worth taking seriously, but not a clear win.

Pooling the trials does not resolve it. A 2025 systematic review and meta-analysis in Frontiers in Cellular and Infection Microbiology combined 11 randomized controlled trials and reported a “significant reduction in 28-day mortality associated with Tα1 administration (OR 0.73, 95%CI: 0.59-0.90, P = 0.003)”. The same paper immediately qualifies it: analyses restricted to “high-quality (OR 0.82, 95%CI: 0.65-1.03, P = 0.09)” and “multi-center (OR 0.86, 95%CI: 0.68-1.08, P = 0.20) subgroups did not reveal a mortality benefit”, and the authors note that “the trial sequential analysis (TSA) suggests that the current sample size is inadequate.” When the benefit shrinks precisely as you restrict the pool to the most rigorous studies, the usual reading is that the true effect is smaller than the overall number, or not yet proven.

The COVID-19 evidence generated the loudest headlines and rests on the weakest design. The most-cited report retrospectively reviewed 76 severe COVID-19 patients at two hospitals in Wuhan, China, and found that “11.11% (4/36) of patients who received Tα1 treatment died, whereas the mortality of severe COVID-19 patients without Tα1 treatment reached 30% (12/40).” The authors themselves wrote that the “results should be interpreted with caution because of the inherent nature of retrospective studies and the small sample size”. Patients were not assigned at random, so the difference could reflect who was chosen for treatment rather than the drug.

How long do people take thymosin alpha 1?

The only course lengths with trial data behind them come from sick patients, and they vary widely by condition. In the ETASS sepsis trial, patients received thymosin alpha-1 for five consecutive days, then once per day for two more days, a one-week course in intensive care. In chronic hepatitis B, the 2020 review describes much longer regimens: one study treated patients for a total of 24 weeks, and it cites another regimen given for 52 weeks.

No trial has set a course length for healthy people using it for general immune support, so there is no evidence-based answer to “how long should I take it” for that purpose. This page does not cover doses.

What are the side effects of thymosin alpha 1?

Where thymosin alpha-1 has been used as a licensed medicine under medical oversight, it has generally looked well tolerated. The 2020 review describes thymalfasin as “usually well tolerated”, with the most common adverse effects being “local irritation, redness, or discomfort at the site of injection.” When it was combined with interferon in trials, the review notes rare side effects such as fever, fatigue, muscle aches, nausea, vomiting, and neutropenia (a drop in a type of white blood cell). In the ETASS sepsis trial, the investigators reported that no Tα1-related severe adverse event was reported and no treatment was discontinued because of side effects.

Who should be cautious. The review lists thymalfasin as contraindicated in people with hypersensitivity to it or its ingredients, and, because it acts on the immune system, in immunosuppressed patients, such as organ transplant recipients, unless the benefits outweigh the risks.

That tolerability record was earned by a manufactured pharmaceutical in supervised trials, and it does not transfer automatically to a research-chemical vial. A “research use only” product is not required to be sterile or to contain the amount on the label. A 2018 peer-reviewed study in Talanta that profiled ten falsified peptide drugs bought from suspected illegal internet pharmacies found “low purity (ranging between 5% and 75% for cysteine containing peptides)”, wide variation in the amount of drug per unit, and toxic elemental impurities including arsenic at concentrations “up to ten times the ICH toxicity limit for parenteral drugs.” For an immune-acting peptide, that stacks an unverified product on top of an experimental use. Our explainer on what the evidence shows about peptide side effects covers both sides in more detail.

Can thymosin alpha-1 be stacked or blended with other peptides?

The best-documented combination in the 2020 review pairs thymosin alpha-1 with interferon for viral hepatitis: the review reports that combination therapy with pegylated interferon “could effectively repress viral replication in hepatitis C patients.” None of the trials cited on this page tested it alongside the research peptides it is mixed with online.

In the community, opinions split. One user lists TA1 among peptides they would not co-mix, while another says blending it with GHK-Cu stopped a histamine reaction they had to GHK-Cu. None of this is tested advice. For how researchers rank the better-studied compounds in this space, see our sister site’s list of the most-researched longevity peptides.

What does thymosin alpha 1 cost?

There is no FDA-approved thymalfasin product in the US to price against. What drives total cost is mainly course length: the trial courses above ran from one week to a year, so the same product can mean very different spending depending on how long someone takes it. Price comparisons between vials also mean less than they appear to when, as the Talanta study found in falsified peptide drugs, the amount of drug per unit can vary widely. For broader context on what peptide and related therapies cost in 2026, see our peptide and GLP-1 therapy cost index.

What are people saying about thymosin alpha-1?

TA1 has a small but enthusiastic following. In the 13 X posts our community tracker collected between July 9 and 16, 2026, the conversation ran along three lines:

• Staying well. A few users describe TA1 as a daily staple and credit it with knocking out early cold symptoms or keeping them healthy when people around them were sick. These are individual anecdotes, with no comparison group and no way to separate the peptide from luck.
• The Zadaxin connection. Users point out that it is approved abroad as Zadaxin for hepatitis B and as cancer-care support, and that it is little known in US biohacking circles. One user compared trying to obtain it for an antiviral regimen to a desperate search.
• Mixing with other peptides. Users disagree about combining it with other peptides, as covered in the stacking section above.

Fact-check. Users are right that thymalfasin is licensed abroad for hepatitis B; the 2020 review confirms approval in more than 35 countries. What the posts leave out is that the same review calls the hepatitis B use now obsolete since direct antiviral drugs arrived, so the licensed track record they point to is for a largely superseded treatment, not for staying well.

These are a small number of self-reports from one platform over one week. They show why people are interested, not whether TA1 prevents illness, which no trial has tested in healthy people.

How to think about thymosin alpha-1

The chemistry is real and interesting: a natural 28-amino-acid immune peptide with a balance-oriented mechanism and an actual life as a licensed medicine in dozens of countries. The popular uses are a different story. Its trials were in hepatitis, sepsis and COVID-19 patients, its main licensed use has been overtaken by newer drugs, and the immune-support and bodybuilding uses that drive US interest have not been tested in any trial cited here. If your actual goal is getting a chronic infection, an autoimmune flare or a stubborn gut problem under better control, start with that goal, ideally with a licensed clinician who can order the right testing.

Status: Not FDA-approved; sold by some telehealth providers as a compounded prescription. What this status means.

Educational information only, not medical advice. Every scientific statement on this page is sourced to the primary references linked above. Updated October 12, 2026.